Compare FSTR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | LUNG |
|---|---|---|
| Founded | 1902 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.8M | 72.2M |
| IPO Year | 1995 | 2020 |
| Metric | FSTR | LUNG |
|---|---|---|
| Price | $28.14 | $1.38 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $32.00 | $5.38 |
| AVG Volume (30 Days) | 19.3K | ★ 711.1K |
| Earning Date | 03-03-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $540,009,000.00 | $90,497,000.00 |
| Revenue This Year | $5.44 | $6.20 |
| Revenue Next Year | $3.05 | $21.61 |
| P/E Ratio | $40.75 | ★ N/A |
| Revenue Growth | 1.74 | ★ 8.01 |
| 52 Week Low | $17.16 | $1.31 |
| 52 Week High | $32.63 | $7.46 |
| Indicator | FSTR | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 38.39 |
| Support Level | $27.26 | N/A |
| Resistance Level | $29.72 | $1.93 |
| Average True Range (ATR) | 1.17 | 0.16 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 42.07 | 5.88 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.